Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/POR_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/POR_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/POR_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/POR_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/POR_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/POR_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003806112 | Oral cavity | LP | NIK/NF-kappaB signaling | 52/4623 | 143/18723 | 1.20e-03 | 9.66e-03 | 52 |
GO:190265211 | Oral cavity | LP | secondary alcohol metabolic process | 53/4623 | 147/18723 | 1.35e-03 | 1.08e-02 | 53 |
GO:001612611 | Oral cavity | LP | sterol biosynthetic process | 27/4623 | 64/18723 | 1.57e-03 | 1.21e-02 | 27 |
GO:001095118 | Oral cavity | LP | negative regulation of endopeptidase activity | 83/4623 | 252/18723 | 1.86e-03 | 1.39e-02 | 83 |
GO:000606613 | Oral cavity | LP | alcohol metabolic process | 111/4623 | 353/18723 | 2.24e-03 | 1.62e-02 | 111 |
GO:000941019 | Oral cavity | LP | response to xenobiotic stimulus | 141/4623 | 462/18723 | 2.33e-03 | 1.68e-02 | 141 |
GO:000657512 | Oral cavity | LP | cellular modified amino acid metabolic process | 64/4623 | 188/18723 | 2.43e-03 | 1.73e-02 | 64 |
GO:001931813 | Oral cavity | LP | hexose metabolic process | 78/4623 | 237/18723 | 2.55e-03 | 1.80e-02 | 78 |
GO:000669511 | Oral cavity | LP | cholesterol biosynthetic process | 24/4623 | 57/18723 | 2.88e-03 | 2.00e-02 | 24 |
GO:190265311 | Oral cavity | LP | secondary alcohol biosynthetic process | 24/4623 | 57/18723 | 2.88e-03 | 2.00e-02 | 24 |
GO:000669412 | Oral cavity | LP | steroid biosynthetic process | 58/4623 | 173/18723 | 5.44e-03 | 3.31e-02 | 58 |
GO:006007015 | Oral cavity | LP | canonical Wnt signaling pathway | 94/4623 | 303/18723 | 6.97e-03 | 3.96e-02 | 94 |
GO:000600614 | Oral cavity | LP | glucose metabolic process | 64/4623 | 196/18723 | 7.09e-03 | 3.98e-02 | 64 |
GO:000820311 | Oral cavity | LP | cholesterol metabolic process | 47/4623 | 137/18723 | 7.20e-03 | 4.04e-02 | 47 |
GO:001612511 | Oral cavity | LP | sterol metabolic process | 51/4623 | 152/18723 | 8.57e-03 | 4.63e-02 | 51 |
GO:001604910 | Prostate | BPH | cell growth | 139/3107 | 482/18723 | 7.53e-12 | 5.90e-10 | 139 |
GO:190165310 | Prostate | BPH | cellular response to peptide | 104/3107 | 359/18723 | 2.51e-09 | 1.00e-07 | 104 |
GO:000155810 | Prostate | BPH | regulation of cell growth | 116/3107 | 414/18723 | 2.66e-09 | 1.05e-07 | 116 |
GO:009013216 | Prostate | BPH | epithelium migration | 104/3107 | 360/18723 | 2.96e-09 | 1.15e-07 | 104 |
GO:009013016 | Prostate | BPH | tissue migration | 105/3107 | 365/18723 | 3.21e-09 | 1.24e-07 | 105 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
POR | SNV | Missense_Mutation | | c.1987G>A | p.Asp663Asn | p.D663N | P16435 | protein_coding | tolerated(0.23) | benign(0.009) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
POR | SNV | Missense_Mutation | rs781866008 | c.838N>A | p.Asp280Asn | p.D280N | P16435 | protein_coding | deleterious(0.03) | benign(0.41) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
POR | SNV | Missense_Mutation | rs782053091 | c.709N>A | p.Glu237Lys | p.E237K | P16435 | protein_coding | deleterious(0.05) | benign(0.182) | TCGA-BH-A0AU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
POR | SNV | Missense_Mutation | novel | c.893N>A | p.Gly298Glu | p.G298E | P16435 | protein_coding | deleterious(0.01) | benign(0.376) | TCGA-GM-A3NY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
POR | insertion | Frame_Shift_Ins | novel | c.937_938insG | p.Ser313CysfsTer6 | p.S313Cfs*6 | P16435 | protein_coding | | | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
POR | insertion | Nonsense_Mutation | novel | c.938_939insTTGAACCTGGGAGG | p.Lys314Ter | p.K314* | P16435 | protein_coding | | | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
POR | deletion | Frame_Shift_Del | novel | c.1514_1524delAGAACGGCGGC | p.Glu505AlafsTer66 | p.E505Afs*66 | P16435 | protein_coding | | | TCGA-AC-A8OQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
POR | deletion | In_Frame_Del | | c.443_445delNNN | p.Thr149del | p.T149del | P16435 | protein_coding | | | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
POR | SNV | Missense_Mutation | rs367782552 | c.773C>T | p.Ala258Val | p.A258V | P16435 | protein_coding | tolerated(0.29) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
POR | SNV | Missense_Mutation | novel | c.1897N>T | p.Gly633Trp | p.G633W | P16435 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5447 | POR | ENZYME, DRUGGABLE GENOME | | sirolimus | SIROLIMUS | 23974086 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | midazolam | MIDAZOLAM | 23324807,19801957 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | cyclosporine | CYCLOSPORINE | 29135906,24658827,24061445 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | zidovudine | ZIDOVUDINE | 22960662 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | atorvastatin | ATORVASTATIN | 25521355 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | nicotine | NICOTINE | |
5447 | POR | ENZYME, DRUGGABLE GENOME | | tacrolimus | TACROLIMUS | 23097010,25322286,26829596,30323313,24113216,26227094,21770725,24921414,24739669,25271728,24061445,28094348,29878980,29399716 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | sunitinib | SUNITINIB | 28117434 |